Obiltoxaximab

Administration

• Type: Monoclonal Antibody
• Dosage Forms: IV
• Routes of Administration: IV
• Common Trade Names: Anthim
• Info: Distributed directly to CDC

Adult Dosing

Inhalation anthrax treatment

• <40 kg
  • 24 mg/kg IV x1
    • Premed with diphenhydramine
• >40 kg
  • 16 mg/kg IV x1
    • Premed with diphenhydramine

Inhalation anthrax prophylaxis, post-exposure

• <40 kg
  • 24 mg/kg IV x1
    • Do not use as 1st line agent
    • Premed with diphenhydramine
• >40 kg
  • 16 mg/kg IV x1
    • Do not use as 1st line agent
    • Premed with diphenhydramine

Pediatric Dosing

Inhalation anthrax treatment

• <15 kg
  • 32 mg/kg IV x1
    • Premed with diphenhydramine
• 16-40 kg
  • 24 mg/kg IV x1
    • Premed with diphenhydramine
• >40 kg
  • 16 mg/kg IV x1
    • Premed with diphenhydramine

Inhalation anthrax prophylaxis, post-exposure

• <15 kg
  • 32 mg/kg IV x1
    • Do not use as 1st line agent
    • Premed with diphenhydramine
• 16-40 kg
  • 24 mg/kg IV x1
    • Do not use as 1st line agent
    • Premed with diphenhydramine
• >40 kg
  • 16 mg/kg IV x1
    • Do not use as 1st line agent
    • Premed with diphenhydramine

Special Populations

• Pregnancy Rating: C; Benefits outweigh risks during pregnancy.
• Lactation risk: L3; Safety unknown

Renal Dosing

• Adult: Not defined
• Pediatric: Not defined

Hepatic Dosing

• Adult: Not defined
• Pediatric: Not defined

Contraindications

• Allergy to class/drug

Adverse Reactions

Serious

• Hypersensitivity reaction
• Anaphylaxis

Common

• Hypersensitivity reaction
• Headache
• URI
• Pruritus
• Cough
• Injection site reaction
• Nasal congestion
• Urticaria
• Extremity pain

Pharmacology

• Half-life: 15-23 Days
• Metabolism: Other; CYP450: unknown
• Excretion: Other

Mechanism of Action

• A monoclonal antibody that binds to anthrax toxin to prevent lethal and edema factors' intracellular entry and neutralizes toxic effects.

See Also

• Bioterrorism
• Anthrax

References

Authors

Jonathan Warren, Ross Donaldson